Clinical investigation of intravenous ciprofloxacin in severe and/or refractory infections in the surgical and gynecological fields

N. Aikawa, Junichi Sasaki, S. Iwai, M. Kunimatsu, H. Furuhata, T. Watanabe, H. Matsuyama, Y. Sugiyama, T. Shimizu, N. Shinagawa, K. Mashita, T. Manabe, S. Ishikawa, A. Mizuno, A. Iwai, Kazuaki Matsumoto, K. Hori, H. Kinoshita, S. Kubo, H. Tanaka & 22 others T. Ueda, M. Fujimoto, S. Nakatani, R. Iwasa, O. Yamazaki, T. Yokoyama, T. Kodama, N. Miyoshi, Y. Maruyama, A. Kishi, G. Takesawa, S. Matsuda, H. Okada, Y. Nakata, J. Okumura, T. Obata, S. Endo, K. Saito, Y. Takahashi, Y. Osakabe, C. Fujii, M. Fukuda

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

A clinical investigation of intravenous ciprofloxacin (CPFX) in the surgical and gynecological fields was conducted in patients with sepsis, peritonitis, biliary tract infections, secondary infections (due to trauma, burns and operative wounds) and gynecological infections, all of which were severe and/or refractory. CPFX was administered intravenously 300 mg twice a day for 3 to 14 days to 87 patients: 4 with sepsis, 22 with peritonitis, 11 with biliary tract infections, 33 with secondary infections, 13 with gynecological infections and 4 with other infections. The clinical efficacy rate was 85.1% (63/74 cases): 100% (2/2 cases) with sepsis, 88.2% (15/17 cases) with peritonitis, 63.6% (7/11 cases) with biliary tract infections, 90.6% (29/32 cases) with secondary infections and 83.3% (10/12 cases) with gynecological infections. The eradication rate of causative organisms was 67.9% (55/81 strains) in terms of bacteriological efficacy. Side effects were noted in 1 case (1.2%) who developed anemia. Abnormal laboratory findings were observed in 18 cases (21.2%) and major findings were increased eosinophil counts and elevated transaminases. The evaluations of overall safety and usefulness were 80.0% (68/85 cases) and 83.8% (62/74 cases), respectively. Therefore, we found that intravenous CPFX is a highly effective drugs for severe and/or refractory surgical infections in the surgical and gynecological fields.

Original languageEnglish
Pages (from-to)936-950
Number of pages15
JournalJapanese Journal of Chemotherapy
Volume45
Issue number11
Publication statusPublished - 1997

Fingerprint

Ciprofloxacin
Infection
Biliary Tract
Peritonitis
Coinfection
Sepsis
Wound Infection
Transaminases
Burns
Eosinophils
Anemia
Safety
Wounds and Injuries
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology

Cite this

Clinical investigation of intravenous ciprofloxacin in severe and/or refractory infections in the surgical and gynecological fields. / Aikawa, N.; Sasaki, Junichi; Iwai, S.; Kunimatsu, M.; Furuhata, H.; Watanabe, T.; Matsuyama, H.; Sugiyama, Y.; Shimizu, T.; Shinagawa, N.; Mashita, K.; Manabe, T.; Ishikawa, S.; Mizuno, A.; Iwai, A.; Matsumoto, Kazuaki; Hori, K.; Kinoshita, H.; Kubo, S.; Tanaka, H.; Ueda, T.; Fujimoto, M.; Nakatani, S.; Iwasa, R.; Yamazaki, O.; Yokoyama, T.; Kodama, T.; Miyoshi, N.; Maruyama, Y.; Kishi, A.; Takesawa, G.; Matsuda, S.; Okada, H.; Nakata, Y.; Okumura, J.; Obata, T.; Endo, S.; Saito, K.; Takahashi, Y.; Osakabe, Y.; Fujii, C.; Fukuda, M.

In: Japanese Journal of Chemotherapy, Vol. 45, No. 11, 1997, p. 936-950.

Research output: Contribution to journalArticle

Aikawa, N, Sasaki, J, Iwai, S, Kunimatsu, M, Furuhata, H, Watanabe, T, Matsuyama, H, Sugiyama, Y, Shimizu, T, Shinagawa, N, Mashita, K, Manabe, T, Ishikawa, S, Mizuno, A, Iwai, A, Matsumoto, K, Hori, K, Kinoshita, H, Kubo, S, Tanaka, H, Ueda, T, Fujimoto, M, Nakatani, S, Iwasa, R, Yamazaki, O, Yokoyama, T, Kodama, T, Miyoshi, N, Maruyama, Y, Kishi, A, Takesawa, G, Matsuda, S, Okada, H, Nakata, Y, Okumura, J, Obata, T, Endo, S, Saito, K, Takahashi, Y, Osakabe, Y, Fujii, C & Fukuda, M 1997, 'Clinical investigation of intravenous ciprofloxacin in severe and/or refractory infections in the surgical and gynecological fields', Japanese Journal of Chemotherapy, vol. 45, no. 11, pp. 936-950.
Aikawa, N. ; Sasaki, Junichi ; Iwai, S. ; Kunimatsu, M. ; Furuhata, H. ; Watanabe, T. ; Matsuyama, H. ; Sugiyama, Y. ; Shimizu, T. ; Shinagawa, N. ; Mashita, K. ; Manabe, T. ; Ishikawa, S. ; Mizuno, A. ; Iwai, A. ; Matsumoto, Kazuaki ; Hori, K. ; Kinoshita, H. ; Kubo, S. ; Tanaka, H. ; Ueda, T. ; Fujimoto, M. ; Nakatani, S. ; Iwasa, R. ; Yamazaki, O. ; Yokoyama, T. ; Kodama, T. ; Miyoshi, N. ; Maruyama, Y. ; Kishi, A. ; Takesawa, G. ; Matsuda, S. ; Okada, H. ; Nakata, Y. ; Okumura, J. ; Obata, T. ; Endo, S. ; Saito, K. ; Takahashi, Y. ; Osakabe, Y. ; Fujii, C. ; Fukuda, M. / Clinical investigation of intravenous ciprofloxacin in severe and/or refractory infections in the surgical and gynecological fields. In: Japanese Journal of Chemotherapy. 1997 ; Vol. 45, No. 11. pp. 936-950.
@article{e78630e6f8b0401080ad767e2f7e44b4,
title = "Clinical investigation of intravenous ciprofloxacin in severe and/or refractory infections in the surgical and gynecological fields",
abstract = "A clinical investigation of intravenous ciprofloxacin (CPFX) in the surgical and gynecological fields was conducted in patients with sepsis, peritonitis, biliary tract infections, secondary infections (due to trauma, burns and operative wounds) and gynecological infections, all of which were severe and/or refractory. CPFX was administered intravenously 300 mg twice a day for 3 to 14 days to 87 patients: 4 with sepsis, 22 with peritonitis, 11 with biliary tract infections, 33 with secondary infections, 13 with gynecological infections and 4 with other infections. The clinical efficacy rate was 85.1{\%} (63/74 cases): 100{\%} (2/2 cases) with sepsis, 88.2{\%} (15/17 cases) with peritonitis, 63.6{\%} (7/11 cases) with biliary tract infections, 90.6{\%} (29/32 cases) with secondary infections and 83.3{\%} (10/12 cases) with gynecological infections. The eradication rate of causative organisms was 67.9{\%} (55/81 strains) in terms of bacteriological efficacy. Side effects were noted in 1 case (1.2{\%}) who developed anemia. Abnormal laboratory findings were observed in 18 cases (21.2{\%}) and major findings were increased eosinophil counts and elevated transaminases. The evaluations of overall safety and usefulness were 80.0{\%} (68/85 cases) and 83.8{\%} (62/74 cases), respectively. Therefore, we found that intravenous CPFX is a highly effective drugs for severe and/or refractory surgical infections in the surgical and gynecological fields.",
author = "N. Aikawa and Junichi Sasaki and S. Iwai and M. Kunimatsu and H. Furuhata and T. Watanabe and H. Matsuyama and Y. Sugiyama and T. Shimizu and N. Shinagawa and K. Mashita and T. Manabe and S. Ishikawa and A. Mizuno and A. Iwai and Kazuaki Matsumoto and K. Hori and H. Kinoshita and S. Kubo and H. Tanaka and T. Ueda and M. Fujimoto and S. Nakatani and R. Iwasa and O. Yamazaki and T. Yokoyama and T. Kodama and N. Miyoshi and Y. Maruyama and A. Kishi and G. Takesawa and S. Matsuda and H. Okada and Y. Nakata and J. Okumura and T. Obata and S. Endo and K. Saito and Y. Takahashi and Y. Osakabe and C. Fujii and M. Fukuda",
year = "1997",
language = "English",
volume = "45",
pages = "936--950",
journal = "Japanese Journal of Chemotherapy",
issn = "1340-7007",
publisher = "Japan Society of Chemotherapy",
number = "11",

}

TY - JOUR

T1 - Clinical investigation of intravenous ciprofloxacin in severe and/or refractory infections in the surgical and gynecological fields

AU - Aikawa, N.

AU - Sasaki, Junichi

AU - Iwai, S.

AU - Kunimatsu, M.

AU - Furuhata, H.

AU - Watanabe, T.

AU - Matsuyama, H.

AU - Sugiyama, Y.

AU - Shimizu, T.

AU - Shinagawa, N.

AU - Mashita, K.

AU - Manabe, T.

AU - Ishikawa, S.

AU - Mizuno, A.

AU - Iwai, A.

AU - Matsumoto, Kazuaki

AU - Hori, K.

AU - Kinoshita, H.

AU - Kubo, S.

AU - Tanaka, H.

AU - Ueda, T.

AU - Fujimoto, M.

AU - Nakatani, S.

AU - Iwasa, R.

AU - Yamazaki, O.

AU - Yokoyama, T.

AU - Kodama, T.

AU - Miyoshi, N.

AU - Maruyama, Y.

AU - Kishi, A.

AU - Takesawa, G.

AU - Matsuda, S.

AU - Okada, H.

AU - Nakata, Y.

AU - Okumura, J.

AU - Obata, T.

AU - Endo, S.

AU - Saito, K.

AU - Takahashi, Y.

AU - Osakabe, Y.

AU - Fujii, C.

AU - Fukuda, M.

PY - 1997

Y1 - 1997

N2 - A clinical investigation of intravenous ciprofloxacin (CPFX) in the surgical and gynecological fields was conducted in patients with sepsis, peritonitis, biliary tract infections, secondary infections (due to trauma, burns and operative wounds) and gynecological infections, all of which were severe and/or refractory. CPFX was administered intravenously 300 mg twice a day for 3 to 14 days to 87 patients: 4 with sepsis, 22 with peritonitis, 11 with biliary tract infections, 33 with secondary infections, 13 with gynecological infections and 4 with other infections. The clinical efficacy rate was 85.1% (63/74 cases): 100% (2/2 cases) with sepsis, 88.2% (15/17 cases) with peritonitis, 63.6% (7/11 cases) with biliary tract infections, 90.6% (29/32 cases) with secondary infections and 83.3% (10/12 cases) with gynecological infections. The eradication rate of causative organisms was 67.9% (55/81 strains) in terms of bacteriological efficacy. Side effects were noted in 1 case (1.2%) who developed anemia. Abnormal laboratory findings were observed in 18 cases (21.2%) and major findings were increased eosinophil counts and elevated transaminases. The evaluations of overall safety and usefulness were 80.0% (68/85 cases) and 83.8% (62/74 cases), respectively. Therefore, we found that intravenous CPFX is a highly effective drugs for severe and/or refractory surgical infections in the surgical and gynecological fields.

AB - A clinical investigation of intravenous ciprofloxacin (CPFX) in the surgical and gynecological fields was conducted in patients with sepsis, peritonitis, biliary tract infections, secondary infections (due to trauma, burns and operative wounds) and gynecological infections, all of which were severe and/or refractory. CPFX was administered intravenously 300 mg twice a day for 3 to 14 days to 87 patients: 4 with sepsis, 22 with peritonitis, 11 with biliary tract infections, 33 with secondary infections, 13 with gynecological infections and 4 with other infections. The clinical efficacy rate was 85.1% (63/74 cases): 100% (2/2 cases) with sepsis, 88.2% (15/17 cases) with peritonitis, 63.6% (7/11 cases) with biliary tract infections, 90.6% (29/32 cases) with secondary infections and 83.3% (10/12 cases) with gynecological infections. The eradication rate of causative organisms was 67.9% (55/81 strains) in terms of bacteriological efficacy. Side effects were noted in 1 case (1.2%) who developed anemia. Abnormal laboratory findings were observed in 18 cases (21.2%) and major findings were increased eosinophil counts and elevated transaminases. The evaluations of overall safety and usefulness were 80.0% (68/85 cases) and 83.8% (62/74 cases), respectively. Therefore, we found that intravenous CPFX is a highly effective drugs for severe and/or refractory surgical infections in the surgical and gynecological fields.

UR - http://www.scopus.com/inward/record.url?scp=0031393637&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031393637&partnerID=8YFLogxK

M3 - Article

VL - 45

SP - 936

EP - 950

JO - Japanese Journal of Chemotherapy

JF - Japanese Journal of Chemotherapy

SN - 1340-7007

IS - 11

ER -